PURPOSE: Parameters to predict outcome and the urodynamic effects during infusion of @entity2951 , seem not to have been assessed in @entity1 with chronic @entity1566 . We monitored bladder activity urodynamically during infusion of high dosage of @entity2951 . MATERIAL AND METHODS: Thirty @entity1 , 18 @entity1 and 12 @entity1 (average age 29 years, range 20-59 years), suffering from chronic spinal @entity602 , who presented a refractory @entity427 , were studied. They received saline solution containing 10(-3) M @entity2951 at a flow rate of 2 ml @entity1009 ) for 15 min (total volume 30 c.c.). The detrusor activity was monitored by a real-time cystometrogram during infusion and 15 min after the end of the infusion itself. New filling cystometrograms were recorded after 30 days and after 6 months. RESULTS: We obtained a clinical and significant urodynamic improvement in 15 of the 30 @entity1 (50%), confirming that intravesical @entity2951 may represent a therapeutic option for a selected group of @entity1 suffering from refractory @entity4681 . Best results were observed in @entity1 who showed, during the infusion of @entity2951 , early @entity1494 which disappeared within 10-12 min from the beginning of the infusion (desensitisation). The @entity1 of this group presented a significant increase of mean cystomanometric capacity after 6 months (from 190.7 to 396.7 ml). No significant clinical or urodynamic improvement was observed in the group of @entity1 in whom uninhibited activity of detrusor was recorded for all the time of infusion. CONCLUSION: Our results support the idea of a major complexity of spinal reflex in paraplegic @entity1 and may offer a clue to explain the failure of therapy with @entity2951 . The present results support a new approach in the treatment of @entity427 . The ideal dosage and treatment interval are not at present established and further studies are needed to explain substantial differences in the outcome according to different urodynamic responses.

Urodynamic assessment during intravesical infusion of XXXX for the treatment of refractory @entity427 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity1494 :: ('MESH:D001745', 'Disease') :: ['uninhibited bladder contractions'] @entity2951 :: ('MESH:D002211', 'Chemical') :: ['capsaicin'] @entity1009 :: ('966', 'Gene') :: ['min(-1'] @entity602 :: ('MESH:D013118', 'Disease') :: ['myelopathy'] @entity4681 :: ('MESH:D016472', 'Disease') :: ['detrusor hyperreflexia due to chronic spinal upper motor neuron lesion'] @entity1566 :: ('MESH:D013119', 'Disease') :: ['cord injury'] @entity427 :: ('MESH:D012021', 'Disease') :: ['detrusor hyperreflexia']
@entity2951 :: (MESH:D002211,Chemical) :: ['capsaicin']
